Significant improvement in quality of life was found with apatinib, in improving insomnia(13) (p = 0·002), ramucirumab in delaying time to deterioration of PS> = 2(10) (p = 0·002) and improving functional functioning and nausea(5) (HR<0·75), bevacizumab in slowing deterioration in pain(4) (p = 0·0068), and endostatin in improving global QoL(11) (p<0·05). This evidence concerns the gene COL18A1 and insomnia.